Uveitic Glaucoma

By Dr Stephen Anesi, MD

Dr. Anesi has 18 years experience as a Uveitis and Corneal Specialist and treats patients with ocular inflammatory diseases including Uveitis, Cataracts, Glaucoma, and Corneal Disease. 

Uveitis is the third leading cause of preventable blindness in this country (USA), but many people who suffer from this group of diseases lose their vision via other another mechanism – Glaucoma.

Glaucoma the “Sneak Thief” of Vision

Glaucoma is the ‘sneak thief’ of vision, a blinding disease of the optic nerve, or the structure that connects your eye and brain and allows you to see.

It causes irreversible vision loss which, at first, is usually completely unnoticed by the patient, asymptomatic, because it affects the ‘peripheral’ vision, but slowly progresses until significant central vision loss occurs.

What Causes Glaucoma and How to Avoid It

Glaucoma itself is actually a much more common disease than Uveitis. It comes in many different forms, is seen on examination by the Uveitis Specialist, and is also monitored by specialized testing of optic nerve “structure” (OCT scan) and “function” (visual field testing), looking for signs of progression of optic nerve damage.

It is estimated that 2 million people worldwide have Uveitis, and that the percentage of patients with Uveitis who also have Glaucoma ranges between 10 and 40%.

Uveitic Glaucoma

I Have Uveitis Should I Be Concerned

Just as in non-uveitic glaucoma, Uveitic Glaucoma is more commonly seen in older patients.

Some forms of Uveitis are more prone to developing Glaucoma, including both infectious causes, such as some types of virus associated Uveitis, and non-infectious causes, like Juvenile Idiopathic Arthritis associated Uveitis.

Sometimes, Uveitic Glaucoma occurs because of long-term dependence on steroid therapy, whether by Oral Medication or Eye Drops, vis-à-vis either poorly controlled inflammation or a distinct and significant rise in eye pressure caused by Steroids themselves.

Uveitic Glaucoma

What Causes Glaucoma and How To Avoid It

Can Uveitis Cause Blindness

The most common reason why Glaucoma causes Vision Loss is because of high pressure in the eye. It is primarily a problem with fluid balance in the eye which creates the pressure – “too much fluid in” or “not enough fluid out”. This imbalance is then treated by means to reduce this pressure such as eye drops or laser therapy, and less commonly surgery.

Cardiovascular and metabolic diseases have also been thought to play a more prominent role in Glaucoma, specifically hypertension and diabetes. But in uveitic glaucoma, several other factors may be in play, including scarring and poor blood flow due to chronic inflammation. Scarring may cause abnormalities in the “outflow” pathway of fluid from the eye, leading to higher pressure. Abnormal blood flow and blood vessel inflammation can also damage outflow pathways, but may also pose a threat to oxygen delivery to the retina and optic nerve (ischemia), which can also cause irreversible damage.

How to Reduce Eye Pressure and Avoid Glaucoma

At times, active inflammation is felt to be the cause of high eye pressure, as may happen in Herpes Simplex Iritis – simply treating the inflammation causes the eye pressure to return to normal.

“This is the reason why the treatment of Uveitic Glaucoma absolutely requires good control of ocular inflammation. Solid control of ocular inflammation can lessen the risk of perpetual vision loss from secondary glaucoma directly caused by or related to this inflammation – uveitic glaucoma.”

Is Uveitis Serious

“And this absolutely must be achieved off of all steroid, achieving steroid free remission of inflammation. The number of providers who understand this premise is thankfully growing, however there still exist providers who are overly concerned about the dangers of systemic therapy for Uveitis and then continue to pour steroid drops on uveitis, keeping it “quiet”, only to let the resulting glaucoma ravage the eye. “

“They do a great disservice to their patients. Better education of Eye Care Providers, including Uveitis and Glaucoma Specialists, about this blinding disease and the ramifications of improper therapy is vital to bridging the gaps in treatment that exist for many of these patients.”

Patient Involvement in Uveitis Treatment

Engaging in discussion of the problem by patients and providers, as well as further development of educational materials, will only help to spread awareness of Uveitic Glaucoma, and the special approach to treatment of this disease.

REFERENCES

1. Dibas A Yorio T.  Glucocorticoid therapy and ocular hypertension. Eur J Pharmacol 2016:787;57-71.

2. Jones III R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: A brief review and update of the literature. Curr Opin Ophthalmol 2006;17-163.

3. Ohji M, Kinoshita S, Ohmi E, et al. Marked intraocular pressure to instillation of corticosteroids in children. Am J Ophthalmol 1991;112:450–454.

4. Kaur S, Dhiman I, Kaushik S, Raj S, Pandav SS. Outcome of ocular steroid hypertensive response in children. J Glaucoma 2016;25:4:343-347.

5. Valenzuela CV, et al. Intranasal corticosteroids do not lead to ocular changes: A systematic review and meta-analysis. Laryngoscope 2019:129;6-12.

6. Desnoeck M, Casteels I, Casteels K. Intraocular pressure elevation in a child due to the use of inhalation steroids—A case report. Bull Soc Belge Ophtalmol 2001;280:97–100.

7. Ritch R, Shields MB, Krupin T. The Glaucomas: Basic Sciences, 2nd ed. Mosby-Year. 1996. 

8. Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS; Difluprednate ophthalmic emulsion 0.05% (Durezol) Study Group. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35:1:26-34.

9. Smith S, Lorenz D, Peace J, McLeod K, Crockett RS, Vogel R. Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery. Clin Ophthalmol 2010;4:983-991. 

10. Kornmann HL, Gedde SJ. Glaucoma management after corneal transplantation surgeries. Curr Opin Ophthalmol 2016;27:2:132-139.

11. Price MO, Price DA, Price FW Jr. Long-term risk of steroid-induced ocular hypertension/glaucoma with topical prednisolone acetate 1% after Descemet stripping endothelial keratoplasty. Cornea 2023. Published ahead of print, June 7.

12. Chew EY, Glassman AR, Beck RW, et al. Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema. Retina 2011;31:2:284-289.

13. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:1:33-55. 

14. Sen HN, Vitale S, Gangaputra SS, Nussenblatt RB, Liesegang TL, Levy-Clarke GA, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Kempen JH. Periocular corticosteroid injections in uveitis: Effects and complications. Ophthalmology 2014;121:11:2275-86.

15. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006;90:999-1003.

16. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normal. Ophthalmology 1984;91;564.

17. Rohen JW. Why is intraocular pressure elevated in chronic simple glaucoma? Ophthalmology 1983;90:7:758-765.

18. Sihota R, Konkal VL, Dada T, Agarwal HC, and Singh R. Prospective, long-term evaluation of steroid-induced glaucoma. Eye 2008;22:1:26–30.

author avatar
Bernandine Johnstone CEO and Medical Device Team Leader
Bernadine is an accomplished entrepreneur and medical device developer with over 20 years of experience in biotech. Diagnosed with uveitis in 1998 and in steroid-free remission since 2008. Passionate about natural healing, Bernadine is dedicated to empowering others to help them navigate their health challenges.